360 Results

People

  1. Lacouture
    Lacouture
  2. Panageas
    Panageas
  3. Wolchok
    Wolchok
  4. Motzer
    Motzer
  5. Postow
    Postow
  6. Houghton
    Houghton
  7. Zelenetz
    Zelenetz
  8. Balagula
    Balagula
  9. Livingston
    Livingston
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (267)
  2. Solid Tumor Oncology Division (171)
  3. Survivorship Research (88)
  4. Division of Subspecialty Medicine (79)
  5. Hematologic Malignancies, Division of (71)
  6. Dermatology (65)
  7. Dermatology Service (63)
  8. GSK Faculty (53)
  9. Melanoma Disease Management Team (47)
  10. Melanoma and Immunotherapeutics Service (47)
  1. "pruritus"
Formats
  1. Journal Article (336)
  2. Review (15)
  3. Research Letter (3)
  4. Editorial (2)
  5. Miscellaneous (2)
  6. Conference Paper (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (267)
  2. Solid Tumor Oncology Division (171)
  3. Survivorship Research (88)
  4. Division of Subspecialty Medicine (79)
  5. Hematologic Malignancies, Division of (71)
  6. Dermatology (65)

More Groups

People
  1. Mario Lacouture (44)
  2. Jedd Wolchok (29)
  3. Katherine Panageas (16)
  4. Paul Chapman (16)
  5. Robert Motzer (14)
  6. Michael Postow (11)

More People

Years
  1. 2025 (11)
  2. 2024 (38)
  3. 2023 (28)
  4. 2022 (12)
  5. 2021 (16)
  6. 2020 (24)

More Years

Publications
  1. Lancet Oncology (30)
  2. Clinical Cancer Research (17)
  3. Journal of Clinical Oncology (17)
  4. Cancer (11)
  5. Journal of the American Academy of Dermatology (11)
  6. Annals of Oncology (9)

More Publications

Publishers
  1. Elsevier Inc. (46)
  2. Elsevier Science, Inc. (39)
  3. Springer (26)
  4. Nature Publishing Group (22)
  5. American Association for Cancer Research (20)
  6. American Society of Clinical Oncology (18)

More Publishers

Results (360)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
    Journal Article

    Hughes, B. G. M.; Guminski, A.; Bowyer, S.; Migden, M. R.; Schmults, C. D.; Khushalani, N. I.; Chang, A. L. S.; Grob, J. J.; Lewis, K. D.; Ansstas, G.; more...
    Journal of the American Academy of Dermatology (2025)

    Fulltext@MSK | Save
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study
    Journal Article

    Zinzani, P. L.; Izutsu, K.; Mehta-Shah, N.; Barta, S. K.; Ishitsuka, K.; CoĢrdoba, R.; Kusumoto, S.; Bachy, E.; Cwynarski, K.; Gritti, G.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: Results from the open-label, randomised, phase II FRACTION-RCC trial
    Journal Article

    Choueiri, T. K.; Kuzel, T. M.; Tykodi, S. S.; Verzoni, E.; Kluger, H.; Nair, S.; Perets, R.; George, S.; Gurney, H.; Pachynski, R. K.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Adavosertib in combination with olaparib in patients with refractory solid tumors: An open-label, dose-finding, and dose-expansion Phase Ib trial
    Journal Article

    Hamilton, E. P.; Falchook, G. S.; Wang, J. S.; Fu, S.; Oza, A. M.; Imedio, E. R.; Kumar, S.; Ottesen, L.; Mugundu, G. M.; de Bruin, E. C.; more...
    Targeted Oncology (2024)

    Fulltext@MSK | Save
  • Updates in the treatment of moderate to severe atopic dermatitis: A focus on JAK inhibitors
    Miscellaneous

    Eng, S.; Vadakkel, G.; DeMatteo, R.
    Pharmacy Times (2024)

    Fulltext@MSK | Save
  • Symptom improvements and adverse effects with Reishi mushroom use: A cross-sectional survey of cancer patients
    Journal Article

    Li, X.; Sun, L.; Chimonas, S.; Li, S. Q.; Feng, P.; Yang, Y.; Mao, J. J.
    Integrative Medicine Research (2024)

    Fulltext@MSK | Save
  • Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: A pharmacovigilance analysis of the FDA Reporting System
    Journal Article

    Storgard, R.; Dusza, S.; Shouval, R.; Scordo, M.; Markova, A.
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: A phase 1 trial
    Journal Article

    Bullock, A. J.; Schlechter, B. L.; Fakih, M. G.; Tsimberidou, A. M.; Grossman, J. E.; Gordon, M. S.; Wilky, B. A.; Pimentel, A.; Mahadevan, D.; Balmanoukian, A. S.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: A phase 1b/2a trial
    Journal Article

    Horwitz, S. M.; Nirmal, A. J.; Rahman, J.; Xu, R.; Drill, E.; Galasso, N.; Ganesan, N.; Davey, T.; Hancock, H.; Perez, L.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Barrier films or dressings for the prevention of acute radiation dermatitis in breast cancer: A systematic review and network meta-analysis
    Review

    Wong, H. C. Y.; Lee, S. F.; Caini, S.; Chan, A. W.; Kwan, J. Y. Y.; Waddle, M.; Sonis, S.; Herst, P.; Alcorn, S.; Bonomo, P.; more...
    Breast Cancer Research and Treatment (2024)

    Fulltext@MSK | Save